Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

Healthcare Drug Manufacturers - Major Medical Care Cannabis
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also operates through SecureDose Synthetics Inc., which is a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.


CSE:PHRX - Post by User

Pharmadrug Inc > 4 out of 5 predictions from Lowfloat are absolute disasters
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(143)
•••
Comment by Lowfloatmining1on Jan 05, 2021 4:13pm
44 Views
Post# 32226168

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:4 out of 5 predictions from Lowfloat are absolute disasters

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:4 out of 5 predictions from Lowfloat are absolute disasters

Yes the entire sector was pumped then dumped! It's still going down some look at the trend. We can agree it's in a downtrend. 

Of course a private placement for more would be good but get real that's not how big fish get rich. They pay less all at the expense of current share holders. 

You compare buzz to canopy come on now.  Canopy is and was a giant to begin with in a much broader cannabis market.  

Terry Booth is NOT a good advisor.  You trash my track record yet promote Booth who screwed up Acb to the point that shareholders will never break even.  Dilution after dilution all while in the growth stage which ended up with millions of write downs.  Save yourself the trouble of spinning Booth in a positive way because he isn't! 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities